These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 956812)

  • 1. Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths.
    Diamond SG; Markham CH
    J Neural Transm; 1976; 38(3-4):259-69. PubMed ID: 956812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing epidemiology of Parkinson's disease: predicted effects of levodopa treatment.
    Marttila RJ; Rinne UK
    Acta Neurol Scand; 1979 Mar; 59(2-3):80-7. PubMed ID: 452843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term responses of Parkinson's disease to levodopa therapy.
    Rinne UK; Sonninen V; Siirtola T; Marttila R
    J Neural Transm Suppl; 1980; (16):149-56. PubMed ID: 6776234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of L-dopa on course of Parkinson's disease.
    Curtis L; Lees AJ; Stern GM; Marmot MG
    Lancet; 1984 Jul; 2(8396):211-2. PubMed ID: 6146763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States.
    Lanska DJ
    J Neurol Sci; 1997 Jan; 145(1):105-8. PubMed ID: 9073037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
    Head J; Ben-Shlomo Y; Lees AJ
    Clin Neuropharmacol; 1998; 21(4):265-6. PubMed ID: 9704171
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H; Siegfried J
    Eur Neurol; 1976; 14(5):321-8. PubMed ID: 949985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality of patients with Parkinson's disease treated with levodopa.
    Marttila RJ; Rinne UK; Siirtola T; Sonninen V
    J Neurol; 1977 Oct; 216(3):147-53. PubMed ID: 72132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence.
    Clarke CE
    Mov Disord; 1995 May; 10(3):250-6. PubMed ID: 7651439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mortality in Parkinson's disease and its modification by levodopa (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Kolb R
    Fortschr Neurol Psychiatr; 1981 May; 49(5):187-92. PubMed ID: 7239405
    [No Abstract]   [Full Text] [Related]  

  • 15. Changing mortality from Parkinson's disease.
    Flaten TP
    Neurology; 1991 Feb; 41(2 ( Pt 1)):329-30. PubMed ID: 1992388
    [No Abstract]   [Full Text] [Related]  

  • 16. Parkinson's disease: progression and mortality.
    Hoehn MM
    Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
    Sweet RD; McDowell FH
    Ann Intern Med; 1975 Oct; 83(4):456-63. PubMed ID: 1166978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-center study of Parkinson mortality with early versus later dopa treatment.
    Diamond SG; Markham CH; Hoehn MM; McDowell FH; Muenter MD
    Ann Neurol; 1987 Jul; 22(1):8-12. PubMed ID: 3631925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.